BeiGene, Ltd/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Ticker
$ONC
Sector
Health
Primary listing
Employees
11,000
Headquarters
Basel, Switzerland
Website
BeiGene, Ltd Metrics
BasicAdvanced
$32B
-
-$1.66
0.27
-
Price and volume
Market cap
$32B
Beta
0.27
52-week high
$313.29
52-week low
$174.74
Average daily volume
414K
Financial strength
Current ratio
2.922
Quick ratio
2.56
Long term debt to equity
5.305
Total debt to equity
27.203
Interest coverage (TTM)
-3.41%
Profitability
EBITDA (TTM)
79.151
Gross margin (TTM)
83.51%
Net profit margin (TTM)
-3.89%
Operating margin (TTM)
-2.23%
Effective tax rate (TTM)
-181.05%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-1.06%
Return on equity (TTM)
-4.98%
Valuation
Price to revenue (TTM)
6.748
Price to book
8.39
Price to tangible book (TTM)
8.54
Price to free cash flow (TTM)
186.763
Free cash flow yield (TTM)
0.54%
Free cash flow per share (TTM)
1.543
Growth
Revenue change (TTM)
47.33%
Earnings per share change (TTM)
-66.85%
3-year revenue growth (CAGR)
62.22%
10-year revenue growth (CAGR)
83.33%
3-year earnings per share growth (CAGR)
-56.84%
10-year earnings per share growth (CAGR)
-7.36%
BeiGene, Ltd News
AllArticlesVideos
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
Business Wire·1 week ago
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
Business Wire·2 weeks ago
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $32B as of August 13, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of August 13, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of August 13, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.